Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1961 1
1962 2
1968 1
1969 2
1973 1
1974 1
1977 1
1982 1
1983 1
1984 1
1985 2
1986 2
1987 3
1988 2
1989 1
1990 1
1991 3
1992 5
1993 2
1994 2
1995 5
1996 7
1997 6
1998 5
1999 4
2000 3
2001 5
2002 5
2003 5
2004 9
2005 12
2006 12
2007 21
2008 31
2009 31
2010 28
2011 30
2012 30
2013 28
2014 45
2015 59
2016 63
2017 56
2018 57
2019 52
2020 57
2021 81
2022 78
2023 79
2024 26

Text availability

Article attribute

Article type

Publication date

Search Results

834 results

Results by year

Filters applied: . Clear all
Page 1
Current knowledge and management of portal vein thrombosis in cirrhosis.
Senzolo M, Garcia-Tsao G, García-Pagán JC. Senzolo M, et al. J Hepatol. 2021 Aug;75(2):442-453. doi: 10.1016/j.jhep.2021.04.029. Epub 2021 Apr 27. J Hepatol. 2021. PMID: 33930474 Review.
Portal vein thrombosis (PVT) is an increasingly recognised complication of cirrhosis whose incidence increases in parallel with the severity of cirrhosis. ...Although the negative effect of complete PVT on the surgical outcome of liver transplant recipients i …
Portal vein thrombosis (PVT) is an increasingly recognised complication of cirrhosis whose incidence increases in parallel with the s …
Long-term albumin administration in decompensated cirrhosis (ANSWER): an open-label randomised trial.
Caraceni P, Riggio O, Angeli P, Alessandria C, Neri S, Foschi FG, Levantesi F, Airoldi A, Boccia S, Svegliati-Baroni G, Fagiuoli S, Romanelli RG, Cozzolongo R, Di Marco V, Sangiovanni V, Morisco F, Toniutto P, Tortora A, De Marco R, Angelico M, Cacciola I, Elia G, Federico A, Massironi S, Guarisco R, Galioto A, Ballardini G, Rendina M, Nardelli S, Piano S, Elia C, Prestianni L, Cappa FM, Cesarini L, Simone L, Pasquale C, Cavallin M, Andrealli A, Fidone F, Ruggeri M, Roncadori A, Baldassarre M, Tufoni M, Zaccherini G, Bernardi M; ANSWER Study Investigators. Caraceni P, et al. Lancet. 2018 Jun 16;391(10138):2417-2429. doi: 10.1016/S0140-6736(18)30840-7. Epub 2018 Jun 1. Lancet. 2018. PMID: 29861076 Clinical Trial.
BACKGROUND: Evidence is scarce on the efficacy of long-term human albumin (HA) administration in patients with decompensated cirrhosis. The human Albumin for the treatmeNt of aScites in patients With hEpatic ciRrhosis (ANSWER) study was designed to clarify this issu …
BACKGROUND: Evidence is scarce on the efficacy of long-term human albumin (HA) administration in patients with decompensated cirrhosis …
Pulmonary hypertension in chronic lung diseases.
Seeger W, Adir Y, Barberà JA, Champion H, Coghlan JG, Cottin V, De Marco T, Galiè N, Ghio S, Gibbs S, Martinez FJ, Semigran MJ, Simonneau G, Wells AU, Vachiéry JL. Seeger W, et al. J Am Coll Cardiol. 2013 Dec 24;62(25 Suppl):D109-16. doi: 10.1016/j.jacc.2013.10.036. J Am Coll Cardiol. 2013. PMID: 24355635 Free article. Review.
Chronic obstructive lung disease (COPD) and diffuse parenchymal lung diseases (DPLD), including idiopathic pulmonary fibrosis (IPF) and sarcoidosis, are associated with a high incidence of pulmonary hypertension (PH), which is linked with exercise limitation and a worse pr …
Chronic obstructive lung disease (COPD) and diffuse parenchymal lung diseases (DPLD), including idiopathic pulmonary fibrosis (IPF) a …
The Heterogeneity of Liver Cancer Metabolism.
Salazar J, Le A. Salazar J, et al. Adv Exp Med Biol. 2021;1311:127-136. doi: 10.1007/978-3-030-65768-0_9. Adv Exp Med Biol. 2021. PMID: 34014539 Free PMC article.
Histologically, it can be divided into two major groups, hepatocellular carcinoma (75% of all liver cancer) and intrahepatic cholangiocarcinoma (15% of all liver cancer) [1, 2]. Primary liver cancer usually happens in liver disease or cirrhosis …
Histologically, it can be divided into two major groups, hepatocellular carcinoma (75% of all liver cancer) and intrahepatic cholangi …
Hepatitis C: Standard of Treatment and What to Do for Global Elimination.
Di Marco L, La Mantia C, Di Marco V. Di Marco L, et al. Viruses. 2022 Feb 28;14(3):505. doi: 10.3390/v14030505. Viruses. 2022. PMID: 35336911 Free PMC article. Review.
Hepatitis C virus infection has a substantial effect on morbidity and mortality worldwide because it is a cause of cirrhosis, hepatocellular carcinoma, liver transplantation, and liver-related death. Direct acting antiviral drugs available today have high eff …
Hepatitis C virus infection has a substantial effect on morbidity and mortality worldwide because it is a cause of cirrhosis, hepatoc …
Inhibition of carnitine palmitoyltransferase 1A in hepatic stellate cells protects against fibrosis.
Fondevila MF, Fernandez U, Heras V, Parracho T, Gonzalez-Rellan MJ, Novoa E, Porteiro B, Alonso C, Mayo R, da Silva Lima N, Iglesias C, Filliol AA, Senra A, Delgado TC, Woodhoo A, Herrero L, Serra D, Prevot V, Schwaninger M, López M, Dieguez C, Millet O, Mato JM, Cubero FJ, Varela-Rey M, Iruzubieta P, Crespo J, Martinez-Chantar ML, Schwabe RF, Nogueiras R. Fondevila MF, et al. J Hepatol. 2022 Jul;77(1):15-28. doi: 10.1016/j.jhep.2022.02.003. Epub 2022 Feb 12. J Hepatol. 2022. PMID: 35167910 Free article.
BACKGROUND & AIMS: The pathogenesis of liver fibrosis requires activation of hepatic stellate cells (HSCs); once activated, HSCs lose intracellular fatty acids but the role of fatty acid oxidation and carnitine palmitoyltransferase 1A (CPT1A) in this process rem …
BACKGROUND & AIMS: The pathogenesis of liver fibrosis requires activation of hepatic stellate cells (HSCs); once activated …
Genetic Ancestry, Race, and Severity of Acutely Decompensated Cirrhosis in Latin America.
Farias AQ, Curto Vilalta A, Momoyo Zitelli P, Pereira G, Goncalves LL, Torre A, Diaz JM, Gadano AC, Mattos AZ, Mendes LSC, Alvares-da-Silva MR, Bittencourt PL, Benitez C, Couto CA, Mendizabal M, Toledo CL, Mazo DFC, Castillo Barradas M, Uson Raposo EM, Padilla-Machaca PM, Zarela Lozano Miranda A, Malé-Velázquez R, Castro Lyra A, Dávalos-Moscol MB, Pérez Hernández JL, Ximenes RO, Faria Silva G, Beltrán-Galvis OA, González Huezo MS, Bessone F, Rocha TDS, Fassio E, Terra C, Marín JI, Sierra Casas P, de la Peña-Ramirez C, Aguilar Parera F, Fernandes F, da Penha Zago-Gomes M, Méndez-Guerrero O, Marciano S, Mattos AA, Oliveira JC, Guerreiro GTS, Codes L, Arrese M, Nardelli MJ, Silva MO, Palma-Fernandez R, Alcantara C, Sánchez Garrido C, Trebicka J, Gustot T, Fernández J, Clària J, Jalan R, Angeli P, Arroyo V, Moreau R, Carrilho FJ; ACLARA Study Collaborators. Farias AQ, et al. Gastroenterology. 2023 Sep;165(3):696-716. doi: 10.1053/j.gastro.2023.05.033. Epub 2023 May 30. Gastroenterology. 2023. PMID: 37263305 Free article.
This study aimed to investigate the association of genetic ancestry and race with acute-on-chronic liver failure (ACLF), which is characterized by acute systemic inflammation, multi-organ failure, and high risk of short-term death. METHODS: This prospective cohort study an …
This study aimed to investigate the association of genetic ancestry and race with acute-on-chronic liver failure (ACLF), which is cha …
UGRP1-modulated MARCO(+) alveolar macrophages contribute to age-related lung fibrosis.
Chen Y, Hao X, Li M, Tian Z, Cheng M. Chen Y, et al. Immun Ageing. 2023 Mar 18;20(1):14. doi: 10.1186/s12979-023-00338-8. Immun Ageing. 2023. PMID: 36934284 Free PMC article.
Upregulated UGRP1was demonstrated to modulate CCL6 production of AMs in the UGRP1-MARCO pair in vivo and in vitro. Furthermore, MARCO(+) AMs aggravated bleomycin-induced pulmonary fibrosis in a CCL6-dependent manner in the aged mice, and blocking MARCO …
Upregulated UGRP1was demonstrated to modulate CCL6 production of AMs in the UGRP1-MARCO pair in vivo and in vitro. Furthermore, MA …
FGF21 gene therapy as treatment for obesity and insulin resistance.
Jimenez V, Jambrina C, Casana E, Sacristan V, Muñoz S, Darriba S, Rodó J, Mallol C, Garcia M, León X, Marcó S, Ribera A, Elias I, Casellas A, Grass I, Elias G, Ferré T, Motas S, Franckhauser S, Mulero F, Navarro M, Haurigot V, Ruberte J, Bosch F. Jimenez V, et al. EMBO Mol Med. 2018 Aug;10(8):e8791. doi: 10.15252/emmm.201708791. EMBO Mol Med. 2018. PMID: 29987000 Free PMC article.
Here, adeno-associated viral vectors (AAV) were used to genetically engineer liver, adipose tissue, or skeletal muscle to secrete FGF21. Treatment of animals under long-term high-fat diet feeding or of ob/ob mice resulted in marked reductions in body weight, adipose tissue …
Here, adeno-associated viral vectors (AAV) were used to genetically engineer liver, adipose tissue, or skeletal muscle to secrete FGF …
Serum identification of at-risk MASH: The metabolomics-advanced steatohepatitis fibrosis score (MASEF).
Noureddin M, Truong E, Mayo R, Martínez-Arranz I, Mincholé I, Banales JM, Arrese M, Cusi K, Arias-Loste MT, Bruha R, Romero-Gómez M, Iruzubieta P, Aller R, Ampuero J, Calleja JL, Ibañez-Samaniego L, Aspichueta P, Martín-Duce A, Kushner T, Ortiz P, Harrison SA, Anstee QM, Crespo J, Mato JM, Sanyal AJ. Noureddin M, et al. Hepatology. 2024 Jan 1;79(1):135-148. doi: 10.1097/HEP.0000000000000542. Epub 2023 Jul 24. Hepatology. 2024. PMID: 37505221 Free PMC article.
METHODS: We included derivation (n = 790) and validation (n = 565) cohorts from international tertiary centers. Patients underwent laboratory assessment and liver biopsy for metabolic dysfunction-associated steatotic liver disease. ...We further compared the perform …
METHODS: We included derivation (n = 790) and validation (n = 565) cohorts from international tertiary centers. Patients underwent laborator …
834 results